MODULE – 18

Dr. Poornimaba shares that Facial hyperpigmentation is a common dermatologic concern that can significantly affect patients’ self-esteem and quality of life. Thiamidol, a potent and selective tyrosinase inhibitor, has emerged as a promising therapeutic option for managing hyperpigmentation disorders. Clinical evidence suggests that 0.2% Thiamidol cream effectively reduces pigmentation intensity while demonstrating a favorable tolerability profile, making it suitable for long-term use. As dermatologists, understanding the efficacy and safety of newer depigmenting agents can help us offer targeted, evidence-based solutions for achieving optimal pigment correction and patient satisfaction